Faruqi & Faruqi Reminds Novo Nordisk Investors of The Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO

Core Insights - The article discusses a class action lawsuit against Novo Nordisk, alleging that the company made misleading statements about its growth potential and market capabilities [2][3]. Group 1: Company Performance - On July 29, 2025, Novo Nordisk announced a reduction in its sales and profit outlook for the second half of 2025, citing lower growth expectations for its products Wegovy and Ozempic due to competition and the persistent use of compounded GLP-1s [3]. - Following the announcement, Novo's stock price dropped from $69.00 to $53.94 per share, marking a decline of approximately 21.83% in one day [3]. Group 2: Legal Proceedings - The lawsuit claims that Novo provided overly positive statements while concealing material adverse facts about its growth potential and market penetration capabilities [2]. - The lead plaintiff in the class action is the investor with the largest financial interest, who will oversee the litigation on behalf of the class [4].